201 related articles for article (PubMed ID: 21671866)
21. Novel approaches for designing 5'-O-ester prodrugs of 3'-azido-2', 3'-dideoxythymidine (AZT).
Parang K; Wiebe LI; Knaus EE
Curr Med Chem; 2000 Oct; 7(10):995-1039. PubMed ID: 10911016
[TBL] [Abstract][Full Text] [Related]
22. Clinical efficacy of a new AT1 blocker.
Philipp T; Heemann U
Basic Res Cardiol; 1998; 93 Suppl 2():51-3. PubMed ID: 9833163
[TBL] [Abstract][Full Text] [Related]
23. Current prodrug design for drug discovery.
Hsieh PW; Hung CF; Fang JY
Curr Pharm Des; 2009; 15(19):2236-50. PubMed ID: 19601825
[TBL] [Abstract][Full Text] [Related]
24. Novel prodrugs with a spontaneous cleavable guanidine moiety.
Hamada Y
Bioorg Med Chem Lett; 2016 Apr; 26(7):1685-9. PubMed ID: 26923694
[TBL] [Abstract][Full Text] [Related]
25. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.
Dang Q; Kasibhatla SR; Reddy KR; Jiang T; Reddy MR; Potter SC; Fujitaki JM; van Poelje PD; Huang J; Lipscomb WN; Erion MD
J Am Chem Soc; 2007 Dec; 129(50):15491-502. PubMed ID: 18041834
[TBL] [Abstract][Full Text] [Related]
26. Prodrug design of phenolic drugs.
Férriz JM; Vinsová J
Curr Pharm Des; 2010; 16(18):2033-52. PubMed ID: 20443775
[TBL] [Abstract][Full Text] [Related]
27. Calixarene: A Versatile Material for Drug Design and Applications.
Hussain MA; Ashraf MU; Muhammad G; Tahir MN; Bukhari SNA
Curr Pharm Des; 2017; 23(16):2377-2388. PubMed ID: 27779081
[TBL] [Abstract][Full Text] [Related]
28. Anticancer prodrugs: an overview of major strategies and recent developments.
Arpicco S; Dosio F; Stella B; Cattel L
Curr Top Med Chem; 2011; 11(18):2346-81. PubMed ID: 21671864
[TBL] [Abstract][Full Text] [Related]
29. N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors.
De Lombaert S; Erion MD; Tan J; Blanchard L; el-Chehabi L; Ghai RD; Sakane Y; Berry C; Trapani AJ
J Med Chem; 1994 Feb; 37(4):498-511. PubMed ID: 8120868
[TBL] [Abstract][Full Text] [Related]
30. Insight into Prodrugs of Quinolones and Fluoroquinolones.
Sharma PC; Piplani M; Mittal M; Pahwa R
Infect Disord Drug Targets; 2016; 16(3):140-161. PubMed ID: 27558786
[TBL] [Abstract][Full Text] [Related]
31. Colchicine prodrugs and codrugs: Chemistry and bioactivities.
Ghawanmeh AA; Chong KF; Sarkar SM; Bakar MA; Othaman R; Khalid RM
Eur J Med Chem; 2018 Jan; 144():229-242. PubMed ID: 29274490
[TBL] [Abstract][Full Text] [Related]
32. Azilsartan medoxomil for the treatment of hypertension.
Vasiliou S
Drugs Today (Barc); 2011 Sep; 47(9):647-51. PubMed ID: 21971539
[TBL] [Abstract][Full Text] [Related]
33. [Prodrugs: goals, principles and outlook].
Piotrovskiĭ LB; Dumpis MA
Farmakol Toksikol; 1988; 51(6):17-25. PubMed ID: 3069492
[TBL] [Abstract][Full Text] [Related]
34. Rational design and development of colon-specific prodrugs.
Dhaneshwar SS; Vadnerkar G
Curr Top Med Chem; 2011; 11(18):2318-45. PubMed ID: 21671865
[TBL] [Abstract][Full Text] [Related]
35. Design of self-immolative linkers for tumour-activated prodrug therapy.
Tranoy-Opalinski I; Fernandes A; Thomas M; Gesson JP; Papot S
Anticancer Agents Med Chem; 2008 Aug; 8(6):618-37. PubMed ID: 18690826
[TBL] [Abstract][Full Text] [Related]
36. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y
J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064
[TBL] [Abstract][Full Text] [Related]
37. Prodrugs of triterpenoids and their derivatives.
Zhou M; Zhang RH; Wang M; Xu GB; Liao SG
Eur J Med Chem; 2017 May; 131():222-236. PubMed ID: 28329729
[TBL] [Abstract][Full Text] [Related]
38. L-Dopa prodrugs: an overview of trends for improving Parkinson's disease treatment.
Di Stefano A; Sozio P; Cerasa LS; Iannitelli A
Curr Pharm Des; 2011; 17(32):3482-93. PubMed ID: 22074421
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.
Devkota L; Lin CM; Strecker TE; Wang Y; Tidmore JK; Chen Z; Guddneppanavar R; Jelinek CJ; Lopez R; Liu L; Hamel E; Mason RP; Chaplin DJ; Trawick ML; Pinney KG
Bioorg Med Chem; 2016 Mar; 24(5):938-956. PubMed ID: 26852340
[TBL] [Abstract][Full Text] [Related]
40. What should be considered on design of a colon-specific prodrug?
Jung Y; Kim YM
Expert Opin Drug Deliv; 2010 Feb; 7(2):245-58. PubMed ID: 20095945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
